h-gamma-Glu-leu-oh

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: h-gamma-Glu-leu-oh
• 英文别名: 2-[(4-amino-4-carboxybutanoyl)amino]-4-methylpentanoic acid
• 化学式: C₁₁H₂₀N₂O₅
• 分子量: 260.29
• InChiKey: MYFMARDICOWMQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] CELLULAR TRANSPORT SYSTEM FOR TRANSFERRING A SULFONIC ACID CONSTRUCT CARRYING A CARGO INTO THE CYTOPLASM OF A CELL<br/>[FR] SYSTÈME DE TRANSPORT CELLULAIRE PERMETTANT DE TRANSFÉRER UNE CONSTRUCTION D'ACIDE SULFONIQUE PORTANT UN CARGO DANS LE CYTOPLASME D'UNE CELLULE
  申请人：SCIENTIST OF FORTUNE SA

  公开号：WO2019068726A1

  公开（公告）日：2019-04-11

  The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfonate transporter located in the cytoplasm membrane of the cell wherein said sulfonate transporter is capable of transporting said sulfonic acid construct across the cytoplasm membrane into the cytoplasm; (ii) a γ-glutamyl transferase (GGT; EC 2.3.2.2) which is modified to be located in the cytoplasm of the cell, wherein said γ-glutamyl transferase is capable of hydrolyzing said sulfonic acid construct so as to release the cargo. Moreover, the present invention relates to the use of a cellular transport system for bringing a sulfonic acid construct which contains a cargo into a cell and releasing the cargo in the cell's cytoplasm. Further, the present invention relates to a γ-glutamyl transferase for hydrolyzing a sulfonic acid construct which contains a cargo.

  本发明涉及一种细胞运输系统，用于将携带货物的磺酸构造体带入细胞并在细胞质中释放货物，所述细胞运输系统包括：（i）位于细胞质膜中的磺酸转运蛋白，其中所述磺酸转运蛋白能够将所述磺酸构造体跨越细胞质膜运输至细胞质；（ii）改性为位于细胞质中的γ-谷氨酰转移酶（GGT；EC 2.3.2.2），其中所述γ-谷氨酰转移酶能够水解所述磺酸构造体以释放货物。此外，本发明涉及使用细胞运输系统将携带货物的磺酸构造体带入细胞并在细胞质中释放货物。此外，本发明涉及用于水解携带货物的磺酸构造体的γ-谷氨酰转移酶。
• Biomarkers for fatty liver disease and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2546649A2

  公开（公告）日：2013-01-16

  The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

  本发明提供了脂肪肝的各种生物标志物，包括脂肪变性和脂肪性肝炎。本发明还提供了使用这些生物标志物的各种方法，包括诊断脂肪肝的方法、确定脂肪肝易感性的方法、监测脂肪肝进展/恶化的方法、评估治疗脂肪肝组合物疗效的方法、筛选组合物调节脂肪肝生物标志物活性的方法、治疗脂肪肝的方法以及基于脂肪肝生物标志物的其他方法。
• Metabolomic profiling of prostate cancer
  申请人：The Regents of the University of Michigan

  公开号：EP2597464A2

  公开（公告）日：2013-05-29

  The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. The present invention further provides diagnostic, research, and therapeutic applications targeting cancer specific metabolites.

  本发明涉及癌症标记物。特别是，本发明提供了在前列腺癌中不同程度存在的代谢物。本发明进一步提供了针对癌症特定代谢物的诊断、研究和治疗应用。
• NOVEL STRAIN OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS CECT 8145 AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF EXCESS WEIGHT AND OBESITY AND ASSOCIATED DISEASES
  申请人：Biopolis, S.L.

  公开号：EP3048165A1

  公开（公告）日：2016-07-27

  The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species Bifidobacterium animalis subsp. lactis CECT 8145, the cell components, metabolites and secreted molecules thereof, which, incorporated into food and/or pharmaceutical formulations, can be used in the treatment and/or prevention of excess weight and obesity and related diseases such as metabolic syndrome, hypertension, glycemia, inflammation, type 2 diabetes, cardiovascular diseases, hypercholesterolemia, hormonal alterations, infertility, etc.

  本发明适用于食品和制药行业。更具体地说，本发明涉及一种新型动物双歧杆菌亚种 CECT 8145 菌株及其细胞成分、代谢产物和分泌分子，将其加入食品和/或药物制剂中，可用于治疗和/或预防超重和肥胖及相关疾病，如代谢综合征、高血压、血糖、炎症、2 型糖尿病、心血管疾病、高胆固醇血症、荷尔蒙改变、不孕症等。
• TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP3410115A1

  公开（公告）日：2018-12-05

  Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.

  本研究提供了肾功能生物标志物以及使用上述生物标志物评估肾功能、监测肾功能、诊断急性肾损伤和诊断慢性肾病的方法。此外，还提供了作为慢性肾病生物标志物的小分子实体套件。